Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 7/20 | 0.48 |
| ▸ | TOP1 | P11387 | 2/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577919 | 0.92 | MT-CO2 (0.52) | MT-CO2TOP1CCR2MEN1RAB9A | |
| SCHEMBL5577568 | 0.88 | LMNA (0.49) | CHRM3MEN1KMT2AMAPTLMNA | |
| SCHEMBL5577911 | 0.87 | MT-CO2 (0.45) | MT-CO2TOP1CHRM3KMT2ALMNA | |
| SCHEMBL5578697 | 0.85 | CXCR3 (0.52) | CHRM3CCR2MEN1KMT2ALMNA | |
| SCHEMBL5577688 | 0.85 | MT-CO2 (0.48) | MT-CO2TOP1LMNACCR5 | |
| SCHEMBL5577630 | 0.83 | MT-CO2 (0.48) | MT-CO2TOP1CHRM3MEN1RAB9A | |
| SCHEMBL5577762 | 0.83 | MT-CO2 (0.49) | MT-CO2TOP1CHRM3MAPTACKR3 | |
| SCHEMBL5577671 | 0.82 | MT-CO2 (0.43) | MT-CO2TOP1MEN1KMT2ALMNA | |
| SCHEMBL5577376 | 0.82 | MAPK8 (0.43) | MT-CO2MEN1KMT2A | |
| SCHEMBL5577901 | 0.82 | MT-CO2 (0.50) | MT-CO2TOP1CHRM3MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | MT-CO2 2047/4885TOP1 2075/4885CHRM3 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.